Kaneka Launches New PCR Take a look at Package for Figuring out the COVID-19 Omicron (BA.1) and “Stealth” Omicron (BA.2) Variants


Enterprise Wire India

in article 1

On March 31, Kaneka Company (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) launched KANEKA RT-PCR Package “SARS-CoV-2 (Omicron/Delta) ver.2”, a real-time PCR check equipment able to concurrently detecting the Omicron (BA.1), “Stealth” Omicron (BA.2), and Delta variants of COVID-19. The equipment has a recommended retail value of 121,000 yen (for 100 checks), together with tax.


This check equipment makes use of a proprietary reagent developed utilizing Kaneka’s molecular testing-related applied sciences to detect the presence of three variants with a single PCR check. That is anticipated to assist scale back the burden positioned by testing and to help with selecting the right appropriate medication and remedy approaches for every variant in scientific settings.


Kaneka has already launched the KANEKA Direct RT-PCR Package SARS-CoV-2, an in-vitro diagnostic reagent that makes use of Kaneka’s authentic pattern processing expertise to provide check leads to lower than an hour, KANEKA RT-PCR Package “SARS-CoV-2 (L452R/E484Q/E484K/N501Y)”, which may detect 4 variants concurrently, and KANEKA RT-PCR Package “SARS-CoV-2 (Omicron/Delta)” which may detect the Delta and Omicron variants of COVID-19. These Kaneka merchandise are getting used at main sporting occasions and for pre-travel PCR testing, in addition to in medical amenities and testing facilities. These merchandise make it doable to rapidly check giant numbers of samples.


Kaneka is taking a variety of measures to fight COVID-19. These embrace the launching of the “An infection Initiative Crew,” which conducts analysis and improvement relating to an infection management measures together with COVID-19, increasing our lineup of PCR check kits, performing contract manufacturing of DNA vaccine APIs and intermediates, creating antibody medication, supplying PCR testing reagents and testing kits, and transport vaccine utilizing temperature-controlled packages.


* Relationship between detected COVID-19 mutations and variants (+: optimistic, -: unfavorable)


(attribute of the BA.1, BA.2)

(attribute of the BA.1)
(attribute of the Delta)












These confer with mutations of the amino acids in viral spike proteins. The names are based mostly on the mutation. Within the E484A mutation, the spike protein has modified from E (glutamine acid) to A (alanine). Within the N856K mutation, the change was from N (asparagine) to Okay (lysine). Within the L452R mutation, it was from L (lysine) to R (arginine).


Inquiry Kind: https://www.kaneka-labtest.com/en/contact-us.html



The content material is by Enterprise Wire India. DKODING Media will not be liable for the content material supplied or any hyperlinks associated to this content material. DKODING Media will not be liable for the correctness, topicality or the standard of the content material.


Please enter your comment!
Please enter your name here